These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 932933)

  • 21. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype.
    von Bahr C; Movin G; Nordin C; Lidén A; Hammarlund-Udenaes M; Hedberg A; Ring H; Sjöqvist F
    Clin Pharmacol Ther; 1991 Mar; 49(3):234-40. PubMed ID: 2007317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A study of the conversion of phenothiazine derivatives to the corresponding sulfoxides on thin-layer plates.
    Kofoed J; Fabierkiewicz C; Lucas GH
    J Chromatogr; 1966 Aug; 23(3):410-6. PubMed ID: 5969493
    [No Abstract]   [Full Text] [Related]  

  • 23. Artifacts in the analysis of thioridazine and other neuroleptics.
    Eap CB; Koeb L; Baumann P
    J Pharm Biomed Anal; 1993 Jun; 11(6):451-7. PubMed ID: 8104489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity.
    Llerena A; Berecz R; de la Rubia A; Norberto MJ; Benítez J
    Ther Drug Monit; 2000 Aug; 22(4):397-401. PubMed ID: 10942178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Light-induced racemization: artifacts in the analysis of the diastereoisomeric pairs of thioridazine 5-sulfoxide in the plasma and urine of patients treated with thioridazine.
    Eap CB; Souche A; Koeb L; Baumann P
    Ther Drug Monit; 1991 Jul; 13(4):356-62. PubMed ID: 1780970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Partitioning of thioridazine and mesoridazine in human blood fractions.
    Dinovo EC; Pollak H; Gottschalk LA
    Methods Find Exp Clin Pharmacol; 1984 Mar; 6(3):143-6. PubMed ID: 6748818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of lactams as in vitro metabolites of piperidine-type phenothiazine antipsychotic drugs.
    Lin G; Chu KW; Damani LA; Hawes EM; Midha KK
    J Pharm Biomed Anal; 1996 Apr; 14(6):727-38. PubMed ID: 8807548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurement of thioridazine in blood and urine.
    Ng CH; Crammer JL
    Br J Clin Pharmacol; 1977 Apr; 4(2):173-83. PubMed ID: 16633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses.
    Salih IS; Thanacoody RH; McKay GA; Thomas SH
    Clin Pharmacol Ther; 2007 Nov; 82(5):548-54. PubMed ID: 17410120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.
    Berecz R; de la Rubia A; Dorado P; Fernández-Salguero P; Dahl ML; LLerena A
    Eur J Clin Pharmacol; 2003 May; 59(1):45-50. PubMed ID: 12682803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of experimental and in silico methods for the assessment of the phototransformation products of the antipsychotic drug/metabolite Mesoridazine.
    Wilde ML; Menz J; Leder C; Kümmerer K
    Sci Total Environ; 2018 Mar; 618():697-711. PubMed ID: 29055596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thioridazine pharmacodynamics: clinical effects may depend upon drug metabolism.
    Lewis MH; Mobilio JN; Rissmiller DJ; Mailman RB
    J Am Osteopath Assoc; 1984 Sep; 84(1 Suppl):124-8. PubMed ID: 6490416
    [No Abstract]   [Full Text] [Related]  

  • 33. Mesoridazine -- a pharmacodynamic and pharmacokinetic profile.
    Gershon S; Sakalis G; Bowers PA
    J Clin Psychiatry; 1981 Dec; 42(12):463-9. PubMed ID: 7031039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A method for the fluorimetric determination of thioridazine (Mellaril) or mesoridazine (Lidanil) in plasma.
    Pacha WL
    Experientia; 1969 Jan; 25(1):103-4. PubMed ID: 5766556
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacokinetics of thioridazine and its metabolites in blood plasma and the brain of rats after acute and chronic treatment.
    Daniel WA; Syrek M; Mach A; Wójcikowski J; Boksa J
    Pol J Pharmacol; 1997; 49(6):439-52. PubMed ID: 9566048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a radioimmunoassay procedure for mesoridazine and its comparison with a high-performance liquid chromatographic method.
    Chakraborty BS; Hawes EM; Midha KK
    Ther Drug Monit; 1987 Dec; 9(4):464-71. PubMed ID: 3424415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The assay of plasma concentration of thioridazine and its metabolites as a function of time.
    Gottschalk LA; Dinovo EC; Nandi BR
    Commun Psychopharmacol; 1978; 2(6):475-9. PubMed ID: 747914
    [No Abstract]   [Full Text] [Related]  

  • 38. No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients.
    Dorado P; Berecz R; Peñas-Lledó EM; de la Rubia A; Llerena A
    Eur J Clin Pharmacol; 2007 May; 63(5):527-8. PubMed ID: 17345072
    [No Abstract]   [Full Text] [Related]  

  • 39. Radioreceptor assay and high-performance liquid chromatography yield similar results for serum thioridazine and its major metabolites.
    Rao ML; Brown WA; Wagner R
    Ther Drug Monit; 1988; 10(2):184-7. PubMed ID: 3381236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma and red cell levels of thioridazine and clinical response in schizophrenia.
    Smith RC; Baumgartner R; Ravichandran GK; Shvartsburd A; Schoolar JC; Allen P; Johnson R
    Psychiatry Res; 1984 Aug; 12(4):287-96. PubMed ID: 6594712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.